Search Videos and More
News
Dana-Farber Research Publication 05.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Course
10th Annual Cancer Disparities Research Symposium
Dana-Farber Cancer Institute's Christopher Lathan, MD, MS, MPH, and Dana-Farber/Harvard Cancer Center's Karen Burns White host the Annual Cancer Disparities Research Symposium in recognition of National Minority Cancer Awareness.
News
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
News
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
News
William Hahn is a 2023 Award of Excellence Honoree by Hope Funds
William Hahn, MD, PhD, executive vice president and chief operating officer at Dana-Farber Cancer Institute, is one of three exceptional individuals honored by Hope Funds with its 2023 Award of Excellence in the areas of Basic Science and Medicine.
Podcast
Season 2, Episode 4: Making it Personal: Targeted Cancer Therapies
By the early 2000s, researchers at Dana-Farber and elsewhere knew that a certain protein appeared in many tumors taken from lung cancer patients. Based on that data, doctors started treating those patients with a drug that inhibited that protein.
Podcast
Season 2, Episode 3: Stop the Division: CDK-4/6 Inhibitors and the Cell Cycle
Cancer is often a problem of cell division; cancer cells keep doubling and doubling, faster and faster.
Symposium
2023 ASCO GU Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2023.
News
Researchers Identify Key Source of T Cell “Exhaustion”
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.
News
Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-Onset Colorectal Cancer
Colorectal cancer among young people is increasing globally and rapidly. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. by the year 2030.
News
A Common Cancer at an Uncommon Age
Colorectal cancer among young people is increasing globally and rapidly. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. by the year 2030.
News
Finding Pancreatic Cancer Earlier - How Dana-Farber is Transforming the Narrative in the Early Detection and Treatment of a Stubborn Cancer
Pancreatic cancer is notoriously difficult to treat. It's commonly discovered at an advanced stage with distant metastases. But innovations in genetic testing and early detection at Dana-Farber are transforming this narrative — giving patients renewed hope for successful long-term treatment and even cures.